Prof Fabrizio Piazza, founding Member & Coordinator The inflammatory Cerebral Amyloid Angiopathy and Alzheimer’s disease Biomarkers (iCAβ) International Network
With WSO and ICAAA, we reported 5 rilevant practical areas: 1. diagnosis, testing, prediction of ICH risk; 2. antithrombotic agents and vascular interventions; 3. vascular risk factors and medications; 4. CAA treatment; 5. diagnosis and treatment of CAA-ri https://t.co/1WkznP1QQb
🚨 PIA Group Webinar Alert 🚨
𝗥𝗲𝘁𝗵𝗶𝗻𝗸𝗶𝗻𝗴 𝗔𝗥𝗜𝗔: Antibody Amplified CAA-ri?
📅 Friday, April 24, 2026
⏰ 9:00 a.m. C.T.
💡 Join our V-PIA and
don’t miss this opportunity to learn from experts and engage in cutting-edge discussion.
https://t.co/hGV3Ll0jpY
#Microbiota-gut-brain axis dysregulation in #Alzheimer’s disease and its modulation through #probiotic supplementation
Fresh new published, congrats to Moira Marizzoni and many thanks to Prof. Annamaria Cattaneo and team!
@iCABNetwork@alzassociation
https://t.co/qo4TNP0CTq
Cerebrospinal Fluid Biomarkers Profiling in Cerebral Amyloid Angiopathy and Relationship With Disease Phenotypes | Journal of the American Heart Association https://t.co/IMPTK6S6Pf
#Donanemab receives positive opinion from the European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) in early symptomatic #Alzheimers disease.
https://t.co/bzJNe1oUN8
#Hemostasis components in cerebral #amyloid angiopathy and #Alzheimer disease
Contribution of hemostasis components to Aβ deposition, endothelial and BBB dysfunction, vessel fragility, cerebral bleeding, and cognitive changes.
https://t.co/bsPdBxAmXD
#donanemab#lecanemab
#Hemostasis components in cerebral #amyloid angiopathy and #Alzheimer disease
Contribution of hemostasis components to Aβ deposition, endothelial and BBB dysfunction, vessel fragility, cerebral bleeding, and cognitive changes.
https://t.co/bsPdBxAmXD
#donanemab#lecanemab
Clinical and Neuroradiological Manifestations of Cerebral Amyloid Angiopathy: A Closer Look into the Natural History of a Frequent Disease
https://t.co/h3p0pFPrD8 #mdpijcm via @JCM_MDPI#vascular_PIA@alzassociation#ICAAA
Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease
https://t.co/7Z4aTsYgdl
Cracking the code of cerebral amyloid angiopathy in AD.
- Neuropathology of CAA and Its Comorbidity with AD (Prof. Jaunmuktane Z)
- Rethinking ARIA in Alzheimer’s Immunotherapy: Iatrogenic CAA-ri. (Prof. Piazza F)
online. Jun 13, 2025 at 4:30pm (CEST)
https://t.co/uHuAWKMhdb
Clinical and Neuroradiological Manifestations of Cerebral Amyloid Angiopathy: A Closer Look into the Natural History of a Frequent Disease https://t.co/DZIBMQ1EOj #mdpijcm
Traumatic Brain Injury and Chronic Traumatic Encephalopathy: Not Only Trigger for Neurodegeneration but Also for Cerebral Amyloid Angiopathy?
https://t.co/whXVjc8cvN #mdpibiomedicines
Clinical and Neuroradiological Manifestations of Cerebral Amyloid Angiopathy: A Closer Look into the Natural History of a Frequent Disease https://t.co/DZIBMQ2cDR #mdpijcm